Retour

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

News Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD did not achieve its primary endpoint, causing a significant drop in the company's stock price.

GlobeNewswire Inc. • 19/09/2024 à 22:00:00
Fulcrum Therapeutics, Inc. Common Stock
Adresse: 26 LANDSDOWNE STREET
Code postal: 02139
Ville: CAMBRIDGE
Region: MA
Numéro de telephone: 617-651-8851
Site internet: https://www.fulcrumtx.com
Status: Active
Info de l'entreprise

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Date de référencement2019-07-18
MarchéStocks
LocaleUS
Echange principalXNAS
TypeCS
DeviseUSD
CIK0001680581
Composite figiBBG00DDY1RK9
Share Class figiBBG00DDY1RM7
Market Cap217,154,680 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employés89
Share Class Shares Outstanding62400000
Weighted Shares Outstanding62400770
Round Lot100
Date de mise à jour2024-09-19
Stats
5 derniers jours
18-09
17-09
16-09
14-09
13-09
Dernier
3.43
3.46
3.185
3.17
3.17
Variation
-0.75%
8.63%
1.43%
0%
-9.3%
Ouverture
3.456
3.185
3.14
3.17
3.495
Plus haut
3.55
3.794
3.336
3.17
3.55
Plus bas
3.549
3.78
3.284
3.17
3.545
Historique
PériodeVarPlus hautPlus bas
1 semaine
-60.74%
8.825
3.17
1 mois
-62.81%
9.5
3.17
3 mois
-46.2%
6.49
3.17
6 mois
-65.49%
10.3399
3.17
1 an
-20.53%
4.39
3.14
3 ans
-88.13%
32.155
2.25
5 ans
-62.09%
9.14
2.25
10 ans
-76.1%
15.94
2.25
Bilans
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-03 2023-11-07 UNPUB
Assets 321,120,000 300,332,000 278,879,000 UNPUB
Current Assets 302,830,000 282,947,000 262,490,000 UNPUB
Current Liabilities 14,407,000 14,804,000 14,075,000 UNPUB
Equity 296,256,000 275,428,000 255,462,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 296,256,000 275,428,000 255,462,000 UNPUB
Liabilities 24,864,000 24,904,000 23,417,000 UNPUB
Liabilities And Equity 321,120,000 300,332,000 278,879,000 UNPUB
Noncurrent Assets 18,290,000 17,385,000 16,389,000 UNPUB
Noncurrent Liabilities 10,457,000 10,100,000 9,342,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-03 2023-11-07 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -364,000 -768,000 -3,886,000 UNPUB
Net Cash Flow, Continuing -364,000 -768,000 -3,886,000 UNPUB
Net Cash Flow From Financing Activities 117,693,000 142,000 0 UNPUB
Net Cash Flow From Financing Activities, Continuing 117,693,000 142,000 0 UNPUB
Net Cash Flow From Investing Activities -93,941,000 19,875,000 19,020,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -93,941,000 19,875,000 19,020,000 UNPUB
Net Cash Flow From Operating Activities -24,116,000 -20,785,000 -22,906,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -24,116,000 -20,785,000 -22,906,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-03 2023-11-07 UNPUB
Comprehensive Income/Loss -24,633,000 -24,332,000 -23,703,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -24,633,000 -24,332,000 -23,703,000 UNPUB
Other Comprehensive Income/Loss 146,000 -549,000 -314,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-03 2023-11-07 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 25,074,000 0 0 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 25,074,000 28,172,000 28,199,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -24,779,000 -23,783,000 -24,017,000 UNPUB
Income/Loss From Continuing Operations Before Tax -24,779,000 880,000 759,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -24,779,000 -23,783,000 -24,017,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -24,779,000 -23,783,000 -24,017,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -24,779,000 -23,783,000 -24,017,000 UNPUB
Operating Expenses 28,235,000 28,172,000 28,199,000 UNPUB
Operating Income/Loss -27,940,000 -27,292,000 -27,440,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 295,000 880,000 759,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-08 2023-03-09
Assets 220,248,000 195,233,000 247,805,000 226,685,000
Current Assets 200,064,000 174,247,000 227,727,000 207,519,000
Current Liabilities 18,288,000 22,121,000 14,699,000 16,725,000
Equity 189,160,000 160,755,000 221,414,000 198,942,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 189,160,000 160,755,000 221,414,000 198,942,000
Liabilities 31,088,000 34,478,000 26,391,000 27,743,000
Liabilities And Equity 220,248,000 195,233,000 247,805,000 226,685,000
Noncurrent Assets 20,184,000 20,986,000 20,078,000 19,166,000
Noncurrent Liabilities 0 0 11,692,000 11,018,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-08 2023-03-09
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -2,099,000 6,840,000 50,785,000 -314,000
Net Cash Flow, Continuing -2,099,000 6,840,000 50,785,000 -314,000
Net Cash Flow From Financing Activities 348,000 2,811,000 80,946,000 84,323,000
Net Cash Flow From Financing Activities, Continuing 348,000 2,811,000 80,946,000 84,323,000
Net Cash Flow From Investing Activities 19,659,000 31,395,000 -2,279,000 12,413,000
Net Cash Flow From Investing Activities, Continuing 19,659,000 31,395,000 -2,279,000 12,413,000
Net Cash Flow From Operating Activities -22,106,000 -27,366,000 -27,882,000 -97,050,000
Net Cash Flow From Operating Activities, Continuing -22,106,000 -27,366,000 -27,882,000 -97,050,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-08 2023-03-09
Comprehensive Income/Loss -25,928,000 -34,070,000 -23,591,000 -110,271,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -26,621,000 -34,048,000 -23,591,000 -110,271,000
Other Comprehensive Income/Loss -693,000 22,000 147,000 -400,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-08 2023-03-09
Basic Earnings Per Share -1 -1 -1 -2
Benefits Costs and Expenses 28,520,000 0 0 116,214,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 28,520,000 36,117,000 25,538,000 116,214,000
Diluted Earnings Per Share -1 -1 -1 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -25,928,000 -34,070,000 -23,738,000 -109,872,000
Income/Loss From Continuing Operations Before Tax -25,928,000 -34,070,000 1,183,000 -109,872,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -25,928,000 -34,070,000 -23,738,000 -109,872,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 -1,000
Net Income/Loss Attributable To Parent -25,928,000 -34,070,000 -23,738,000 -109,871,000
Net Income/Loss Available To Common Stockholders, Basic -25,928,000 -34,070,000 -23,738,000 -109,871,000
Operating Expenses 28,590,000 36,117,000 25,538,000 118,903,000
Operating Income/Loss -25,998,000 -34,235,000 -24,355,000 -112,561,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 2,592,000 1,882,000 1,183,000 6,342,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-10 2021-11-04 2022-03-03
Assets 156,476,000 137,879,000 255,547,000 235,000,000
Current Assets 146,987,000 128,511,000 246,187,000 225,998,000
Current Liabilities 22,631,000 22,510,000 20,597,000 19,199,000
Equity 127,754,000 110,890,000 230,609,000 211,539,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 127,754,000 110,890,000 230,609,000 211,539,000
Liabilities 28,722,000 26,989,000 24,938,000 23,461,000
Liabilities And Equity 156,476,000 137,879,000 255,547,000 235,000,000
Noncurrent Assets 9,489,000 9,368,000 9,360,000 9,002,000
Noncurrent Liabilities 0 0 4,341,000 4,262,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-10 2021-11-04 2022-03-03
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 43,693,000 -43,966,000 8,694,000 -21,640,000
Net Cash Flow, Continuing 43,693,000 -43,966,000 8,694,000 -21,640,000
Net Cash Flow From Financing Activities 47,504,000 209,000 137,903,000 186,507,000
Net Cash Flow From Financing Activities, Continuing 47,504,000 209,000 137,903,000 186,507,000
Net Cash Flow From Investing Activities 12,415,000 -26,354,000 -106,636,000 -129,669,000
Net Cash Flow From Investing Activities, Continuing 12,415,000 -26,354,000 -106,636,000 -129,669,000
Net Cash Flow From Operating Activities -16,226,000 -17,821,000 -22,573,000 -78,478,000
Net Cash Flow From Operating Activities, Continuing -16,226,000 -17,821,000 -22,573,000 -78,478,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-10 2021-11-04 2022-03-03
Comprehensive Income/Loss -16,999,000 -19,648,000 -20,794,000 -81,242,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -17,001,000 -19,653,000 -20,794,000 -81,242,000
Other Comprehensive Income/Loss -2,000 -5,000 -78,000 -395,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-10 2021-11-04 2022-03-03
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 21,788,000 0 0 100,010,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 21,788,000 24,063,000 25,705,000 100,010,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,999,000 -19,648,000 -20,716,000 -80,847,000
Income/Loss From Continuing Operations Before Tax -16,999,000 -19,648,000 4,935,000 -80,847,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,999,000 -19,648,000 -20,716,000 -80,847,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,999,000 -19,648,000 -20,716,000 -80,847,000
Net Income/Loss Available To Common Stockholders, Basic -16,999,000 -19,648,000 -20,716,000 -80,847,000
Operating Expenses 21,832,000 24,063,000 25,705,000 100,217,000
Operating Income/Loss -17,043,000 -19,682,000 -20,770,000 -81,054,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 4,789,000 4,381,000 4,935,000 19,163,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-11 2020-11-10 2021-03-04
Assets 94,856,000 144,862,000 142,215,000 129,577,000
Current Assets 84,323,000 134,784,000 132,112,000 119,510,000
Current Liabilities 14,182,000 13,943,000 26,455,000 26,725,000
Equity 70,631,000 122,131,000 104,985,000 95,181,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 70,631,000 122,131,000 104,985,000 95,181,000
Liabilities 24,225,000 22,731,000 37,230,000 34,396,000
Liabilities And Equity 94,856,000 144,862,000 142,215,000 129,577,000
Noncurrent Assets 10,533,000 10,078,000 10,103,000 10,067,000
Noncurrent Liabilities 0 0 10,775,000 7,671,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-11 2020-11-10 2021-03-04
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -71,334,000 50,339,000 9,503,000 -39,661,000
Net Cash Flow, Continuing -71,334,000 50,339,000 9,503,000 -39,661,000
Net Cash Flow From Financing Activities 274,000 64,686,000 -83,000 71,132,000
Net Cash Flow From Financing Activities, Continuing 274,000 64,686,000 -83,000 71,132,000
Net Cash Flow From Investing Activities -56,404,000 -226,000 14,090,000 -57,138,000
Net Cash Flow From Investing Activities, Continuing -56,404,000 -226,000 14,090,000 -57,138,000
Net Cash Flow From Operating Activities -15,204,000 -14,121,000 -4,504,000 -53,655,000
Net Cash Flow From Operating Activities, Continuing -15,204,000 -14,121,000 -4,504,000 -53,655,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-11 2020-11-10 2021-03-04
Comprehensive Income/Loss -18,452,000 -15,685,000 -19,012,000 -70,821,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -18,505,000 -15,551,000 -19,012,000 -70,821,000
Other Comprehensive Income/Loss -53,000 134,000 -50,000 -2,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-11 2020-11-10 2021-03-04
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 19,202,000 0 0 79,642,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 19,202,000 17,924,000 20,952,000 79,642,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -18,452,000 -15,685,000 -18,962,000 -70,819,000
Income/Loss From Continuing Operations Before Tax -18,452,000 -15,685,000 1,848,000 -70,819,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -18,452,000 -15,685,000 -18,962,000 -70,819,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -18,452,000 -15,685,000 -18,962,000 -70,819,000
Net Income/Loss Available To Common Stockholders, Basic -18,452,000 -15,685,000 -18,962,000 -70,819,000
Operating Expenses 19,546,000 17,924,000 20,952,000 80,434,000
Operating Income/Loss -18,796,000 -15,924,000 -19,104,000 -71,611,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 750,000 2,000,000 1,848,000 8,823,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-14 2020-03-05
Assets UNPUB UNPUB 115,956,000 110,439,000
Current Assets UNPUB UNPUB 105,222,000 100,083,000
Current Liabilities UNPUB UNPUB 8,585,000 12,140,000
Equity UNPUB UNPUB 102,128,000 87,153,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 102,128,000 87,153,000
Liabilities UNPUB UNPUB 13,828,000 23,286,000
Liabilities And Equity UNPUB UNPUB 115,956,000 110,439,000
Noncurrent Assets UNPUB UNPUB 10,734,000 10,356,000
Noncurrent Liabilities UNPUB UNPUB 5,243,000 11,146,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-14 2020-03-05
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 51,969,000 23,916,000
Net Cash Flow, Continuing UNPUB UNPUB 51,969,000 23,916,000
Net Cash Flow From Financing Activities UNPUB UNPUB 65,200,000 64,343,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 65,200,000 64,343,000
Net Cash Flow From Investing Activities UNPUB UNPUB -214,000 -944,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -214,000 -944,000
Net Cash Flow From Operating Activities UNPUB UNPUB -13,017,000 -39,483,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -13,017,000 -39,483,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-14 2020-03-05
Comprehensive Income/Loss UNPUB UNPUB -16,542,000 -82,677,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -16,542,000 -82,677,000
Other Comprehensive Income/Loss UNPUB UNPUB 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2019-11-14 2020-03-05
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -16,542,000 -82,677,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -16,542,000 -82,677,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -16,542,000 -82,677,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -16,542,000 -82,677,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -17,338,000 -89,805,000
Operating Expenses UNPUB UNPUB 17,006,000 84,217,000
Operating Income/Loss UNPUB UNPUB -17,006,000 -84,217,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 796,000 7,128,000
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 796,000 7,128,000
Revenues UNPUB UNPUB 0 0
Calendrier économique
19 Septembre 2024 (heure UTC) Actuel Précédent Consensus
★★
13:00
United States
SEP
1.592
1.883
★
11:30
United States
SEP 17
4.700
4.965
★
11:30
United States
★
11:30
United States
SEP 17
4.690
4.990
★
11:30
United States
★
08:30
United States
Q2
-266800000000.000
-241000000000.000
-259000000000.000
★
10:30
United States
SEP 13
58000000000.000
40000000000.000
53000000000.000
★
10:30
United States
SEP 13
-96000000000.000
★★
10:00
United States
AUG
-2.500
1.500
★★
16:30
United States
SEP 18
7100000000000.000
7115000000000.000
★
08:30
United States
SEP 15
227500.000
231000.000
★
08:30
United States
SEP
34.000
24.000
★
16:30
United States
SEP 18
3217000000000.000
3360000000000.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:FULC240719C00001000 OCASPS Call American 100 1 BATO 2024-07-19
O:FULC240719C00002000 OCASPS Call American 100 2 BATO 2024-07-19
O:FULC240719C00003000 OCASPS Call American 100 3 BATO 2024-07-19
O:FULC240719C00004000 OCASPS Call American 100 4 BATO 2024-07-19
O:FULC240719C00005000 OCASPS Call American 100 5 BATO 2024-07-19
O:FULC240719C00006000 OCASPS Call American 100 6 BATO 2024-07-19
O:FULC240719C00007000 OCASPS Call American 100 7 BATO 2024-07-19
O:FULC240719C00008000 OCASPS Call American 100 8 BATO 2024-07-19
O:FULC240719C00009000 OCASPS Call American 100 9 BATO 2024-07-19
O:FULC240719C00010000 OCASPS Call American 100 10 BATO 2024-07-19
O:FULC240719C00011000 OCASPS Call American 100 11 BATO 2024-07-19
O:FULC240719C00012000 OCASPS Call American 100 12 BATO 2024-07-19
O:FULC240719C00013000 OCASPS Call American 100 13 BATO 2024-07-19
O:FULC240719C00014000 OCASPS Call American 100 14 BATO 2024-07-19
O:FULC240719C00015000 OCASPS Call American 100 15 BATO 2024-07-19
O:FULC240719C00016000 OCASPS Call American 100 16 BATO 2024-07-19
O:FULC240719P00001000 OPASPS Put American 100 1 BATO 2024-07-19
O:FULC240719P00002000 OPASPS Put American 100 2 BATO 2024-07-19
O:FULC240719P00003000 OPASPS Put American 100 3 BATO 2024-07-19
O:FULC240719P00004000 OPASPS Put American 100 4 BATO 2024-07-19
O:FULC240719P00005000 OPASPS Put American 100 5 BATO 2024-07-19
O:FULC240719P00006000 OPASPS Put American 100 6 BATO 2024-07-19
O:FULC240719P00007000 OPASPS Put American 100 7 BATO 2024-07-19
O:FULC240719P00008000 OPASPS Put American 100 8 BATO 2024-07-19
O:FULC240719P00009000 OPASPS Put American 100 9 BATO 2024-07-19
O:FULC240719P00010000 OPASPS Put American 100 10 BATO 2024-07-19
O:FULC240719P00011000 OPASPS Put American 100 11 BATO 2024-07-19
O:FULC240719P00012000 OPASPS Put American 100 12 BATO 2024-07-19
O:FULC240719P00013000 OPASPS Put American 100 13 BATO 2024-07-19
O:FULC240719P00014000 OPASPS Put American 100 14 BATO 2024-07-19
O:FULC240719P00015000 OPASPS Put American 100 15 BATO 2024-07-19
O:FULC240719P00016000 OPASPS Put American 100 16 BATO 2024-07-19
O:FULC240621C00009000 OCASPS Call American 100 9 BATO 2024-06-21
O:FULC240621C00010000 OCASPS Call American 100 10 BATO 2024-06-21
O:FULC240621C00011000 OCASPS Call American 100 11 BATO 2024-06-21
O:FULC240621C00012000 OCASPS Call American 100 12 BATO 2024-06-21
O:FULC240621C00013000 OCASPS Call American 100 13 BATO 2024-06-21
O:FULC240621C00014000 OCASPS Call American 100 14 BATO 2024-06-21
O:FULC240621C00015000 OCASPS Call American 100 15 BATO 2024-06-21
O:FULC240621C00016000 OCASPS Call American 100 16 BATO 2024-06-21
O:FULC240621C00017000 OCASPS Call American 100 17 BATO 2024-06-21
O:FULC240621C00018000 OCASPS Call American 100 18 BATO 2024-06-21
O:FULC240621C00020000 OCASPS Call American 100 20 BATO 2024-06-21
O:FULC240621P00009000 OPASPS Put American 100 9 BATO 2024-06-21
O:FULC240621P00010000 OPASPS Put American 100 10 BATO 2024-06-21
O:FULC240621P00011000 OPASPS Put American 100 11 BATO 2024-06-21
O:FULC240621P00012000 OPASPS Put American 100 12 BATO 2024-06-21
O:FULC240621P00013000 OPASPS Put American 100 13 BATO 2024-06-21
O:FULC240621P00014000 OPASPS Put American 100 14 BATO 2024-06-21
O:FULC240621P00015000 OPASPS Put American 100 15 BATO 2024-06-21
O:FULC240621P00016000 OPASPS Put American 100 16 BATO 2024-06-21
O:FULC240621P00017000 OPASPS Put American 100 17 BATO 2024-06-21
O:FULC240621P00018000 OPASPS Put American 100 18 BATO 2024-06-21
O:FULC240621P00020000 OPASPS Put American 100 20 BATO 2024-06-21
O:FULC240621C00008000 OCASPS Call American 100 8 BATO 2024-06-21
O:FULC240621P00008000 OPASPS Put American 100 8 BATO 2024-06-21
O:FULC240621C00001000 OCASPS Call American 100 1 BATO 2024-06-21
O:FULC240621C00002000 OCASPS Call American 100 2 BATO 2024-06-21
O:FULC240621C00003000 OCASPS Call American 100 3 BATO 2024-06-21
O:FULC240621C00004000 OCASPS Call American 100 4 BATO 2024-06-21
O:FULC240621C00005000 OCASPS Call American 100 5 BATO 2024-06-21
O:FULC240621C00006000 OCASPS Call American 100 6 BATO 2024-06-21
O:FULC240621C00007000 OCASPS Call American 100 7 BATO 2024-06-21
O:FULC240621P00001000 OPASPS Put American 100 1 BATO 2024-06-21
O:FULC240621P00002000 OPASPS Put American 100 2 BATO 2024-06-21
O:FULC240621P00003000 OPASPS Put American 100 3 BATO 2024-06-21
O:FULC240621P00004000 OPASPS Put American 100 4 BATO 2024-06-21
O:FULC240621P00005000 OPASPS Put American 100 5 BATO 2024-06-21
O:FULC240621P00006000 OPASPS Put American 100 6 BATO 2024-06-21
O:FULC240621P00007000 OPASPS Put American 100 7 BATO 2024-06-21
O:FULC240517C00001000 OCASPS Call American 100 1 BATO 2024-05-17
O:FULC240517C00002000 OCASPS Call American 100 2 BATO 2024-05-17
O:FULC240517P00001000 OPASPS Put American 100 1 BATO 2024-05-17
O:FULC240517P00002000 OPASPS Put American 100 2 BATO 2024-05-17
O:FULC240517C00003000 OCASPS Call American 100 3 BATO 2024-05-17
O:FULC240517C00004000 OCASPS Call American 100 4 BATO 2024-05-17
O:FULC240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:FULC240517C00006000 OCASPS Call American 100 6 BATO 2024-05-17
O:FULC240517C00007000 OCASPS Call American 100 7 BATO 2024-05-17
O:FULC240517C00008000 OCASPS Call American 100 8 BATO 2024-05-17
O:FULC240517C00009000 OCASPS Call American 100 9 BATO 2024-05-17
O:FULC240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:FULC240517C00011000 OCASPS Call American 100 11 BATO 2024-05-17
O:FULC240517C00012000 OCASPS Call American 100 12 BATO 2024-05-17
O:FULC240517C00013000 OCASPS Call American 100 13 BATO 2024-05-17
O:FULC240517C00014000 OCASPS Call American 100 14 BATO 2024-05-17
O:FULC240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:FULC240517C00016000 OCASPS Call American 100 16 BATO 2024-05-17
O:FULC240517C00017000 OCASPS Call American 100 17 BATO 2024-05-17
O:FULC240517C00018000 OCASPS Call American 100 18 BATO 2024-05-17
O:FULC240517C00019000 OCASPS Call American 100 19 BATO 2024-05-17
O:FULC240517P00003000 OPASPS Put American 100 3 BATO 2024-05-17
O:FULC240517P00004000 OPASPS Put American 100 4 BATO 2024-05-17
O:FULC240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:FULC240517P00006000 OPASPS Put American 100 6 BATO 2024-05-17
O:FULC240517P00007000 OPASPS Put American 100 7 BATO 2024-05-17
O:FULC240517P00008000 OPASPS Put American 100 8 BATO 2024-05-17
O:FULC240517P00009000 OPASPS Put American 100 9 BATO 2024-05-17
O:FULC240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:FULC240517P00011000 OPASPS Put American 100 11 BATO 2024-05-17
O:FULC240517P00012000 OPASPS Put American 100 12 BATO 2024-05-17
O:FULC240517P00013000 OPASPS Put American 100 13 BATO 2024-05-17
O:FULC240517P00014000 OPASPS Put American 100 14 BATO 2024-05-17
O:FULC240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:FULC240517P00016000 OPASPS Put American 100 16 BATO 2024-05-17
O:FULC240517P00017000 OPASPS Put American 100 17 BATO 2024-05-17
O:FULC240517P00018000 OPASPS Put American 100 18 BATO 2024-05-17
O:FULC240517P00019000 OPASPS Put American 100 19 BATO 2024-05-17
O:FULC240419C00018000 OCASPS Call American 100 18 BATO 2024-04-19
O:FULC240419C00020000 OCASPS Call American 100 20 BATO 2024-04-19
O:FULC240419P00018000 OPASPS Put American 100 18 BATO 2024-04-19
O:FULC240419P00020000 OPASPS Put American 100 20 BATO 2024-04-19
O:FULC240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:FULC240419C00002000 OCASPS Call American 100 2 BATO 2024-04-19
O:FULC240419C00003000 OCASPS Call American 100 3 BATO 2024-04-19
O:FULC240419C00004000 OCASPS Call American 100 4 BATO 2024-04-19
O:FULC240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:FULC240419C00006000 OCASPS Call American 100 6 BATO 2024-04-19
O:FULC240419C00007000 OCASPS Call American 100 7 BATO 2024-04-19
O:FULC240419C00008000 OCASPS Call American 100 8 BATO 2024-04-19
O:FULC240419C00009000 OCASPS Call American 100 9 BATO 2024-04-19
O:FULC240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:FULC240419C00011000 OCASPS Call American 100 11 BATO 2024-04-19
O:FULC240419C00012000 OCASPS Call American 100 12 BATO 2024-04-19
O:FULC240419C00013000 OCASPS Call American 100 13 BATO 2024-04-19
O:FULC240419C00014000 OCASPS Call American 100 14 BATO 2024-04-19
O:FULC240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:FULC240419C00016000 OCASPS Call American 100 16 BATO 2024-04-19
O:FULC240419C00017000 OCASPS Call American 100 17 BATO 2024-04-19
O:FULC240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:FULC240419P00002000 OPASPS Put American 100 2 BATO 2024-04-19
O:FULC240419P00003000 OPASPS Put American 100 3 BATO 2024-04-19
O:FULC240419P00004000 OPASPS Put American 100 4 BATO 2024-04-19
O:FULC240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:FULC240419P00006000 OPASPS Put American 100 6 BATO 2024-04-19
O:FULC240419P00007000 OPASPS Put American 100 7 BATO 2024-04-19
O:FULC240419P00008000 OPASPS Put American 100 8 BATO 2024-04-19
O:FULC240419P00009000 OPASPS Put American 100 9 BATO 2024-04-19
O:FULC240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:FULC240419P00011000 OPASPS Put American 100 11 BATO 2024-04-19
O:FULC240419P00012000 OPASPS Put American 100 12 BATO 2024-04-19
O:FULC240419P00013000 OPASPS Put American 100 13 BATO 2024-04-19
O:FULC240419P00014000 OPASPS Put American 100 14 BATO 2024-04-19
O:FULC240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:FULC240419P00016000 OPASPS Put American 100 16 BATO 2024-04-19
O:FULC240419P00017000 OPASPS Put American 100 17 BATO 2024-04-19
O:FULC240315C00014000 OCASPS Call American 100 14 BATO 2024-03-15
O:FULC240315P00014000 OPASPS Put American 100 14 BATO 2024-03-15
O:FULC240315C00012000 OCASPS Call American 100 12 BATO 2024-03-15
O:FULC240315C00013000 OCASPS Call American 100 13 BATO 2024-03-15
O:FULC240315P00012000 OPASPS Put American 100 12 BATO 2024-03-15
O:FULC240315P00013000 OPASPS Put American 100 13 BATO 2024-03-15
O:FULC240315C00011000 OCASPS Call American 100 11 BATO 2024-03-15
O:FULC240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:FULC240315P00011000 OPASPS Put American 100 11 BATO 2024-03-15
O:FULC240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:FULC240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:FULC240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:FULC240315C00009000 OCASPS Call American 100 9 BATO 2024-03-15
O:FULC240315P00009000 OPASPS Put American 100 9 BATO 2024-03-15
O:FULC240315C00001000 OCASPS Call American 100 1 BATO 2024-03-15
O:FULC240315C00004000 OCASPS Call American 100 4 BATO 2024-03-15
O:FULC240315C00006000 OCASPS Call American 100 6 BATO 2024-03-15
O:FULC240315P00001000 OPASPS Put American 100 1 BATO 2024-03-15
O:FULC240315P00004000 OPASPS Put American 100 4 BATO 2024-03-15
O:FULC240315P00006000 OPASPS Put American 100 6 BATO 2024-03-15
O:FULC240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:FULC240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:FULC240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:FULC240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:FULC240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:FULC240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:FULC240216C00011000 OCASPS Call American 100 11 BATO 2024-02-16
O:FULC240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:FULC240216P00011000 OPASPS Put American 100 11 BATO 2024-02-16
O:FULC240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:FULC240216C00001000 OCASPS Call American 100 1 BATO 2024-02-16
O:FULC240216C00002000 OCASPS Call American 100 2 BATO 2024-02-16
O:FULC240216C00003000 OCASPS Call American 100 3 BATO 2024-02-16
O:FULC240216C00004000 OCASPS Call American 100 4 BATO 2024-02-16
O:FULC240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:FULC240216C00006000 OCASPS Call American 100 6 BATO 2024-02-16
O:FULC240216C00007000 OCASPS Call American 100 7 BATO 2024-02-16
O:FULC240216C00008000 OCASPS Call American 100 8 BATO 2024-02-16
O:FULC240216C00009000 OCASPS Call American 100 9 BATO 2024-02-16
O:FULC240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:FULC240216P00001000 OPASPS Put American 100 1 BATO 2024-02-16
O:FULC240216P00002000 OPASPS Put American 100 2 BATO 2024-02-16
O:FULC240216P00003000 OPASPS Put American 100 3 BATO 2024-02-16
O:FULC240216P00004000 OPASPS Put American 100 4 BATO 2024-02-16
O:FULC240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:FULC240216P00006000 OPASPS Put American 100 6 BATO 2024-02-16
O:FULC240216P00007000 OPASPS Put American 100 7 BATO 2024-02-16
O:FULC240216P00008000 OPASPS Put American 100 8 BATO 2024-02-16
O:FULC240216P00009000 OPASPS Put American 100 9 BATO 2024-02-16
O:FULC240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:FULC240119C00011000 OCASPS Call American 100 11 BATO 2024-01-19
O:FULC240119C00014000 OCASPS Call American 100 14 BATO 2024-01-19
O:FULC240119P00011000 OPASPS Put American 100 11 BATO 2024-01-19
O:FULC240119P00014000 OPASPS Put American 100 14 BATO 2024-01-19
O:FULC240119C00001000 OCASPS Call American 100 1 BATO 2024-01-19
O:FULC240119C00004000 OCASPS Call American 100 4 BATO 2024-01-19
O:FULC240119C00006000 OCASPS Call American 100 6 BATO 2024-01-19
O:FULC240119C00009000 OCASPS Call American 100 9 BATO 2024-01-19
O:FULC240119P00001000 OPASPS Put American 100 1 BATO 2024-01-19
O:FULC240119P00004000 OPASPS Put American 100 4 BATO 2024-01-19
O:FULC240119P00006000 OPASPS Put American 100 6 BATO 2024-01-19
O:FULC240119P00009000 OPASPS Put American 100 9 BATO 2024-01-19
O:FULC240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:FULC240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:FULC240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:FULC240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:FULC240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:FULC240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:FULC240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:FULC240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:FULC240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:FULC240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:FULC240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:FULC240119C00035000 OCASPS Call American 100 35 BATO 2024-01-19
O:FULC240119C00040000 OCASPS Call American 100 40 BATO 2024-01-19
O:FULC240119C00045000 OCASPS Call American 100 45 BATO 2024-01-19
O:FULC240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:FULC240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:FULC240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:FULC240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:FULC240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:FULC240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:FULC240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:FULC240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:FULC240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:FULC240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:FULC240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:FULC240119P00035000 OPASPS Put American 100 35 BATO 2024-01-19
O:FULC240119P00040000 OPASPS Put American 100 40 BATO 2024-01-19
O:FULC240119P00045000 OPASPS Put American 100 45 BATO 2024-01-19
O:FULC231215C00009000 OCASPS Call American 100 9 BATO 2023-12-15
O:FULC231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:FULC231215P00009000 OPASPS Put American 100 9 BATO 2023-12-15
O:FULC231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:FULC231215C00001000 OCASPS Call American 100 1 BATO 2023-12-15
O:FULC231215C00004000 OCASPS Call American 100 4 BATO 2023-12-15
O:FULC231215C00006000 OCASPS Call American 100 6 BATO 2023-12-15
O:FULC231215P00001000 OPASPS Put American 100 1 BATO 2023-12-15
O:FULC231215P00004000 OPASPS Put American 100 4 BATO 2023-12-15
O:FULC231215P00006000 OPASPS Put American 100 6 BATO 2023-12-15
O:FULC231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:FULC231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:FULC231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:FULC231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:FULC231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:FULC231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:FULC231117C00001000 OCASPS Call American 100 1 BATO 2023-11-17
O:FULC231117C00002000 OCASPS Call American 100 2 BATO 2023-11-17
O:FULC231117C00003000 OCASPS Call American 100 3 BATO 2023-11-17
O:FULC231117C00004000 OCASPS Call American 100 4 BATO 2023-11-17
O:FULC231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:FULC231117C00006000 OCASPS Call American 100 6 BATO 2023-11-17
O:FULC231117C00007000 OCASPS Call American 100 7 BATO 2023-11-17
O:FULC231117C00008000 OCASPS Call American 100 8 BATO 2023-11-17
O:FULC231117C00009000 OCASPS Call American 100 9 BATO 2023-11-17
O:FULC231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:FULC231117P00001000 OPASPS Put American 100 1 BATO 2023-11-17
O:FULC231117P00002000 OPASPS Put American 100 2 BATO 2023-11-17
O:FULC231117P00003000 OPASPS Put American 100 3 BATO 2023-11-17
O:FULC231117P00004000 OPASPS Put American 100 4 BATO 2023-11-17
O:FULC231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:FULC231117P00006000 OPASPS Put American 100 6 BATO 2023-11-17
O:FULC231117P00007000 OPASPS Put American 100 7 BATO 2023-11-17
O:FULC231117P00008000 OPASPS Put American 100 8 BATO 2023-11-17
O:FULC231117P00009000 OPASPS Put American 100 9 BATO 2023-11-17
O:FULC231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:FULC231020C00001000 OCASPS Call American 100 1 BATO 2023-10-20
O:FULC231020C00002000 OCASPS Call American 100 2 BATO 2023-10-20
O:FULC231020C00003000 OCASPS Call American 100 3 BATO 2023-10-20
O:FULC231020C00004000 OCASPS Call American 100 4 BATO 2023-10-20
O:FULC231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:FULC231020C00006000 OCASPS Call American 100 6 BATO 2023-10-20
O:FULC231020C00007000 OCASPS Call American 100 7 BATO 2023-10-20
O:FULC231020C00008000 OCASPS Call American 100 8 BATO 2023-10-20
O:FULC231020C00009000 OCASPS Call American 100 9 BATO 2023-10-20
O:FULC231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:FULC231020P00001000 OPASPS Put American 100 1 BATO 2023-10-20
O:FULC231020P00002000 OPASPS Put American 100 2 BATO 2023-10-20
O:FULC231020P00003000 OPASPS Put American 100 3 BATO 2023-10-20
O:FULC231020P00004000 OPASPS Put American 100 4 BATO 2023-10-20
O:FULC231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:FULC231020P00006000 OPASPS Put American 100 6 BATO 2023-10-20
O:FULC231020P00007000 OPASPS Put American 100 7 BATO 2023-10-20
O:FULC231020P00008000 OPASPS Put American 100 8 BATO 2023-10-20
O:FULC231020P00009000 OPASPS Put American 100 9 BATO 2023-10-20
O:FULC231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:FULC230915C00009000 OCASPS Call American 100 9 BATO 2023-09-15
O:FULC230915P00009000 OPASPS Put American 100 9 BATO 2023-09-15
O:FULC230915C00001000 OCASPS Call American 100 1 BATO 2023-09-15
O:FULC230915C00004000 OCASPS Call American 100 4 BATO 2023-09-15
O:FULC230915C00006000 OCASPS Call American 100 6 BATO 2023-09-15
O:FULC230915P00001000 OPASPS Put American 100 1 BATO 2023-09-15
O:FULC230915P00004000 OPASPS Put American 100 4 BATO 2023-09-15
O:FULC230915P00006000 OPASPS Put American 100 6 BATO 2023-09-15
O:FULC230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:FULC230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:FULC230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:FULC230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:FULC230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:FULC230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:FULC230915C00017500 OCASPS Call American 100 17.5 BATO 2023-09-15
O:FULC230915C00020000 OCASPS Call American 100 20 BATO 2023-09-15
O:FULC230915C00022500 OCASPS Call American 100 22.5 BATO 2023-09-15
O:FULC230915C00025000 OCASPS Call American 100 25 BATO 2023-09-15
O:FULC230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:FULC230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:FULC230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:FULC230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:FULC230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:FULC230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:FULC230915P00017500 OPASPS Put American 100 17.5 BATO 2023-09-15
O:FULC230915P00020000 OPASPS Put American 100 20 BATO 2023-09-15
O:FULC230915P00022500 OPASPS Put American 100 22.5 BATO 2023-09-15
O:FULC230915P00025000 OPASPS Put American 100 25 BATO 2023-09-15
O:FULC230818C00001000 OCASPS Call American 100 1 BATO 2023-08-18
O:FULC230818C00004000 OCASPS Call American 100 4 BATO 2023-08-18
O:FULC230818C00006000 OCASPS Call American 100 6 BATO 2023-08-18
O:FULC230818P00001000 OPASPS Put American 100 1 BATO 2023-08-18
O:FULC230818P00004000 OPASPS Put American 100 4 BATO 2023-08-18
O:FULC230818P00006000 OPASPS Put American 100 6 BATO 2023-08-18
O:FULC230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
O:FULC230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:FULC230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:FULC230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:FULC230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:FULC230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:FULC230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:FULC230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
O:FULC230818C00022500 OCASPS Call American 100 22.5 BATO 2023-08-18
O:FULC230818C00025000 OCASPS Call American 100 25 BATO 2023-08-18
O:FULC230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:FULC230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:FULC230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:FULC230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:FULC230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:FULC230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:FULC230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:FULC230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:FULC230818P00022500 OPASPS Put American 100 22.5 BATO 2023-08-18
O:FULC230818P00025000 OPASPS Put American 100 25 BATO 2023-08-18
Flux d'actualités
News Fulcrum Therapeutics
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
Fulcrum Therapeutics, Inc. announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD did not achieve its primary endpoint, causing a significant drop in the company's stock price.
GlobeNewswire Inc. • Il y a 6 jours
News Fulcrum Therapeutics
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
Fulcrum Therapeutics' (FULC) stock plunged 61.1% after its phase III study for treating facioscapulohumeral muscular dystrophy (FSHD) failed to meet its primary endpoint. The company has decided to stop further development of the drug losmapimod for FSHD but is advancing another pipeline candidate, pociredir, for sickle cell disease.
Benzinga • Il y a 6 jours
News Fulcrum Therapeutics
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics' Phase 3 REACH trial of losmapimod for the treatment of FSHD did not meet its primary endpoint. The company plans to suspend further development of losmapimod and focus on advancing other programs, including pociredir for sickle cell disease.
GlobeNewswire Inc. • Il y a 1 semaine
News Fulcrum Therapeutics
Fulcrum Therapeutics renforce son équipe de direction en nommant Isabel Kalofonos au poste de directeur commercial et Heather Faulds au poste de directeur des affaires réglementaires et de l'assurance qualité
Fulcrum Therapeutics a annoncé les nominations d'Isabel Kalofonos au poste de Chief Commercial Officer et de Heather Faulds au poste de Chief Regulatory Affairs & Quality Assurance Officer. Ces nominations permettront de faire progresser le losmapimod, le principal médicament candidat de la société, en vue d'une éventuelle demande d'autorisation de mise sur le marché (NDA) et d'un lancement commercial.
GlobeNewswire Inc. • Il y a 1 mois
Stocks Licensing Agreements
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ―
GlobeNewswire Inc. • Il y a 4 mois
News Conference Calls/ Webcasts
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2024 financial results will be released on Monday, May 13, 2024 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
GlobeNewswire Inc. • Il y a 4 mois
Stocks Changes in company's own shares
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • Il y a 6 mois
stocks Changes in company's own shares
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • Il y a 6 mois
Management Directors and Officers
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ―
GlobeNewswire Inc. • Il y a 6 mois
Calendar Calendar of Events
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the Leerink Partners Global Biopharma Conference, being held in Miami, FL on Wednesday, March 13, 2024 at 9:20 a.m. ET. Management will also participate in one-on-one investor meetings.
GlobeNewswire Inc. • Il y a 6 mois
Voir tous
Actualités liées
Dernières actualités

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT